<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01141881</url>
  </required_header>
  <id_info>
    <org_study_id>2202</org_study_id>
    <nct_id>NCT01141881</nct_id>
  </id_info>
  <brief_title>Evaluation of the Role of Intravitreal Tissue Plasminogen Activator in Treatment of Refractory Diabetic Macular Edema</brief_title>
  <official_title>Evaluation of the Role of Intravitreal Injection of TPA in Treatment of Refractory Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mashhad University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mashhad University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: to evaluate the effect of intravitreal injection of tissue plasminogen
      activator(tPA) in treatment of refractory diabetic macular edema(DME).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    occurrence of retinal hemorrhage , increase in macular edema of some patients in TPA group
  </why_stopped>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Anticipated">January 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>TPA,IVB,F/U</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tissue Plasminogen Activator,bevacizumab ,follow up</intervention_name>
    <description>25 microgram in 0.05 cc,1.25 mg in 0.05 cc,nothing</description>
    <arm_group_label>TPA,IVB,F/U</arm_group_label>
    <other_name>bevacizumab :avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. type 2 diabetes

          2. Non proliferative diabetic retinopathy(NPDR) stage of diabetic retinopathy

          3. patients with refractory DME CSME (patients with the last MPC at least 3 months before
             and no improvement was observed in BCVA, macular thickness inOCT, clinical examination
             and fundus photographs of patients )

          4. Absence of PVD in the B-scan

          5. Absence of PVD in OCT of macular area and optic disk

          6. Absence of PVD in slit lamp biomicroscopy(SLE)

          7. the last PRP session was at least 3 months ago.

          8. Absence of traction on macula in clinical examination and OCT

        Exclusion Criteria:

          1. One eye patients

          2. Patients who are candidates for intraocular surgery.

          3. Patients with the history of glaucoma or ocular hypertension

          4. Patients with a history of vitrectomy in the study eye

          5. Not being able to refer for the next visits

          6. Eyes with cataract that makes the assessment of the macula impossible.

          7. Intraretinal hemorrhage at fovea that will interfere with OCT.

          8. BCVA â‰¤ 0.1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>naser shoeibi, MD</last_name>
    <role>Study Director</role>
    <affiliation>mashhad university of medical science</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Khatam Hospital</name>
      <address>
        <city>Mashhad</city>
        <state>Khorasan Razavi</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <reference>
    <citation>Murakami T, Takagi H, Ohashi H, Kita M, Nishiwaki H, Miyamoto K, Watanabe D, Sakamoto A, Yamaike N, Yoshimura N. Role of posterior vitreous detachment induced by intravitreal tissue plasminogen activator in macular edema with central retinal vein occlusion. Retina. 2007 Oct;27(8):1031-7.</citation>
    <PMID>18040240</PMID>
  </reference>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2010</study_first_submitted>
  <study_first_submitted_qc>June 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2010</study_first_posted>
  <last_update_submitted>October 7, 2010</last_update_submitted>
  <last_update_submitted_qc>October 7, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>naser shoeibi</name_title>
    <organization>Professor assistant of ophthalmology</organization>
  </responsible_party>
  <keyword>Tissue Plasminogen activator,</keyword>
  <keyword>Clinically significant macular edema,</keyword>
  <keyword>Refractory Diabetic macular edema ,</keyword>
  <keyword>posterior vitreous detachment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Plasminogen</mesh_term>
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

